Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Inotiv Ord Shs (NOTV)  
$2.14 0.10 (4.46%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 15,830,000
Market Cap: 33.88(M)
Last Volume: 86,028 Avg Vol: 76,335
52 Week Range: $1.69 - $11.04
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Inotiv is a contract research organization providing drug discovery and development services to the pharmaceutical, chemical, and medical device industries, and sells analytical instruments to the pharmaceutical development and contract research industries. Co.'s segments include: contract research services, which provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing; and research products, which designs, develops, manufactures and markets in vivo sampling systems and accessories, physiology monitoring tools, and liquid chromatography and electrochemistry instruments platforms.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 52,966 52,966 72,966
Total Buy Value $0 $163,981 $163,981 $445,856
Total People Bought 0 2 2 3
Total Buy Transactions 0 2 2 6
Total Shares Sold 0 0 0 5,123
Total Sell Value $0 $0 $0 $58,709
Total People Sold 0 0 0 2
Total Sell Transactions 0 0 0 4
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 243
  Page 7 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Leasure Robert Jr. President and CEOOfficer   •       •      –    2019-01-12 3/A IO $0.00 $0 I/I 0 26,100     -
   Kissinger Candice B 10% Owner   –       –       •   2018-09-14 4 B $1.74 $17,382 D/D 10,000 1,033,457 2.37     -
   Neff R Matthew Director   –       •      –    2018-09-14 4 B $1.66 $4,150 D/D 2,500 15,000 2.31     -
   Blumhoff Jill VP, Finance & CFO   •       –      –    2018-09-13 4 A $1.62 $729 D/D 450 1,311     -
   Neff R Matthew Director   –       •      –    2018-09-12 4 A $1.65 $4,125 D/D 2,500 12,500     -
   Downing Philip A Sr. VP, Preclinical Srvcs.   •       –      –    2018-09-11 4 B $1.67 $8,350 D/D 5,000 20,765 2.74     -
   Downing Philip A Sr. VP, Preclinical Srvcs.   •       –      –    2018-02-16 4 B $1.46 $7,300 D/D 5,000 15,765 2.74     -
   Neff R Matthew Director   –       •      –    2017-09-08 4 B $1.50 $7,500 D/D 5,000 10,000 2.39     -
   Davis Gregory Cole Director   –       •      –    2017-08-18 4 B $1.70 $8,500 D/D 5,000 5,000 2.39     -
   Neff R Matthew Director   –       •      –    2017-08-18 4 B $1.70 $8,500 D/D 5,000 5,000 2.39     -
   Blumhoff Jill VP, Finance & CFO   •       –      –    2017-03-15 4 D $1.66 $2,721 D/D (1,639) 861     -
   Blumhoff Jill VP, Finance & CFO   •       –      –    2017-03-15 4 OE $1.01 $2,720 D/D 2,500 1,283     -
   Downing Philip A VP, Preclinical Srvcs.   •       –      –    2017-03-01 4 D $1.62 $10,101 D/D (6,235) 10,765     -
   Downing Philip A VP, Preclinical Srvcs.   •       –      –    2017-03-01 4 OE $1.01 $10,100 D/D 10,000 17,000     -
   Dougherty Connie Leigh VP, Business Development   •       –      –    2016-05-27 4 B $0.92 $389 D/D 423 9,074 2.66     -
   Dougherty Connie Leigh VP, Business Development   •       –      –    2016-05-23 4 B $0.92 $88 D/D 96 8,651 2.66     -
   Dougherty Connie Leigh VP, Business Development   •       –      –    2016-05-19 4 B $0.92 $1,523 D/D 1,655 8,555 2.66     -
   Lemke Jacqueline M President and CEO   •       •      –    2016-02-29 4 B $1.17 $7,020 I/I 6,000 9,000 2.58     -
   Lemke Jacqueline M President and CEO   •       •      –    2016-02-29 4 B $1.19 $4,742 D/D 4,000 60,685 2.73     -
   Downing Philip A VP, Preclinical Srvcs.   •       –      –    2015-09-14 4 B $1.73 $5,190 D/D 3,000 7,000 2.74     -
   Dougherty Connie Leigh VP, Business Development   •       –      –    2015-08-21 4 B $1.42 $9,798 D/D 6,900 6,900 2.74     -
   Lemke Jacqueline M President and CEO   •       •      –    2015-06-18 4 D $2.12 $205,248 D/D (96,815) 56,685     -
   Lemke Jacqueline M President and CEO   •       •      –    2015-06-18 4 OE $1.38 $173,200 D/D 125,500 153,500     -
   Lemke Jacqueline M President and CEO   •       •      –    2015-02-27 4 B $2.04 $6,120 I/I 3,000 3,000 2.58     -
   Lemke Jacqueline M President and CEO   •       •      –    2015-02-27 4 B $2.04 $14,280 D/D 7,000 28,000 2.81     -
  243 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us